Effect of self knee taping versus therapist knee taping in people with patellofemoral osteoarthritis
The effect of self taping on pain and function in people with mild to moderate radiographic severity patellofemoral knee osteoarthritis
King Khaled General Hospital
20 participants
Sep 12, 2013
Interventional
Conditions
Summary
Osteoarthritis (OA) is a global problem, commonly developed in the knee joint. The prevalence of radiographic tibiofemoral osteoarthritis (TFOA) in elderly American subjects is about 44% in those 80 years or older, whereas it is only 27% in those younger than 80 with a slight higher percentage in women than men . The prevalence of patellofemroal osteoarthritis (PFOA) is approximately at same percentage, in patients with degenerative changes of the knee; about half has arthritis in patellofemoral joints. McAlindon, Snow et al. (1992) was among the firsts who investigated the prevalence of PFOA in UK and worldwide; authors reported that 19% of men and 34% of women over the age of 55 have radiographic degenerative changes isolated to the patellofemoral joint in a community based British study. Davies, Vince et al. (2002). Therapeutic taping (clinical-based) has been used extensively in physiotherapy practice. However, with no availability of cure and progressive nature of patellofemroal osteoarthritis, there is urgent need to test whether simpler and easier to apply taping technique are effective or not. Self taping is a cost-effective and easier to apply technique comparing to clinical-based patellar taping. This clinical trial aims to explore whether this technique (self patellar taping ) able to produce similar effects compared with commonly used therapeutic taping or not.
Eligibility
Inclusion Criteria1
- i) Confirmed diagnosis of Mild to moderate of isolated Patellofemroal or co-existed with tibiofemoral knee osteoarthritis; ii) aged at least 35 years at the time of treatment; iii) pain during aggravating activities present on most days during the past month; and v) radiographic OA severity of greater than or equal to 2 on Kellgren and Lawrence grading (Kellgren, 1957).
Exclusion Criteria1
- i) concomitant pain from hip or lumbar spine; ii) recent knee injections (3 months); iii) planned lower limb surgery in the following 6 months; iv) knee or hip arthroplasty or osteotomy; v) Any history of skin problems prevent application of patellar taping; vii) inability to understand written and spoken Arabic/English.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: Commercially hypoallergenic knee tape (Hypafix) will be tested. The knee tape will be used to induce medial gliding of knee patella. Tape will be applied by physiotherapist 1 in Arm 1. In Arm 2, Tape will be applied by patient after getting detailed instructions from physiotherapist 2. In order to improve adherence from patients in arm 2, Patients will be required to report date and time of taping sessions, and return of unused tape. Patients in both groups will be contacted every 3-4 days to confirm appointment date (arm 1) or ensure ability to apply self taping. An independent investigator (observer 1) will open the sealed opaque envelope indicating whether patient will be allocated in arm 1 or arm 2. In addition, he will collect questionnaires after final treatment from observer 2. The outcome investigator (observer 2) will remain blinded to test condition (therapist taping vs. Self taping) for the study duration. He will be responsible for distribution and collecting questionnaires at baseline and post-treatment and send them to observer 1. Arm 1: Therapeutic tape will be applied by Physiotherapist 1 Arm 2: Therapeutic tape will be applied by patient himself with supervision by physiotherapist 2. Exposure: The tape will be applied for 6 weeks starting from first treatment session. Tape will be replaced every 3-4 days at clinic for arm 1. Subjects in arm 2 will be supplied with pre-cut tape to apply at home with detailed instructions.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001259730